



patiromer sorbitex calcium 8.4g and 16.8g powder for oral suspension (Veltassa®)

Vifor Fresenius Medical Care Renal Pharma UK Ltd

09 July 2021

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and, following review by the SMC executive, advises NHS Boards and Area Drug and Therapeutics Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission

patiromer sorbitex calcium (Veltassa®) is accepted for restricted use within NHSScotland.

Indication under review: treatment of hyperkalaemia in adults.

SMC restriction: patients with hyperkalaemia (defined as a serum potassium of >6.0mmol/L) with chronic kidney disease (CKD) stage 3b to 5 and/or heart failure, who would otherwise need to down-titrate or discontinue their renin-angiotensin-aldosterone system inhibitor (RAASi) therapy to maintain a clinically acceptable serum potassium level (normokalaemia).

Patiromer sorbitex calcium offers an additional treatment choice in the therapeutic class of non-absorbed cation-exchange compounds that act as selective potassium binders.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

This assessment is based on data submitted by the applicant company up to and including 09 June 2021.

Chairman
Scottish Medicines Committee